Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 2022 Nov 2;127(12):2249. doi: 10.1038/s41416-022-02043-7

Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial

Shukui Qin 1,#, Jin Li 2,✉,#, Haijun Zhong 3, Chuan Jin 4, Lili Chen 5, Xianglin Yuan 6, Qingxia Fan 7, Kehe Chen 8, Peiguo Cao 9, Jianjun Xiao 10, Da Jiang 11, Tao Zhang 12, Hongyu Zhang 13, Xicheng Wang 14, Wei Wang 15, Lin Han 16, Qingyu Wang 16, Jun Zhu 16; the Serplulimab-MSI-H Investigators
PMCID: PMC9727148  PMID: 36323881

Correction to: British Journal of Cancer 10.1038/s41416-022-02001-3, published online 19 October 2022

The original version of this article contained a mistake in the PDF as the corresponding author Jin Li is missing from the Consortia information. We apologize for the error. The original article has been corrected.


Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES